Search

Your search keyword '"Louise D. Johnson"' showing total 3 results
Start Over Author "Louise D. Johnson" Topic drug discovery
3 results on '"Louise D. Johnson"'

1. Discovery of an In Vivo Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones

Author

Alice C. Harnden, Owen A. Davis, Gary M. Box, Angela Hayes, Louise D. Johnson, Alan T. Henley, Alexis K. de Haven Brandon, Melanie Valenti, Kwai-Ming J. Cheung, Alfie Brennan, Rosemary Huckvale, Olivier A. Pierrat, Rachel Talbot, Michael D. Bright, Hafize Aysin Akpinar, Daniel S. J. Miller, Dalia Tarantino, Sharon Gowan, Selby de Klerk, Peter Craig McAndrew, Yann-Vaï Le Bihan, Mirco Meniconi, Rosemary Burke, Vladimir Kirkin, Rob L. M. van Montfort, Florence I. Raynaud, Olivia W. Rossanese, Benjamin R. Bellenie, and Swen Hoelder

Subjects
Drug Discovery, Molecular Medicine
Published
2023
Full Text
View/download PDF

2. Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 In Vivo

Author

Rosemary Huckvale, Alice C. Harnden, Kwai-Ming J. Cheung, Olivier A. Pierrat, Rachel Talbot, Gary M. Box, Alan T. Henley, Alexis K. de Haven Brandon, Albert E. Hallsworth, Michael D. Bright, Hafize Aysin Akpinar, Daniel S. J. Miller, Dalia Tarantino, Sharon Gowan, Angela Hayes, Emma A. Gunnell, Alfie Brennan, Owen A. Davis, Louise D. Johnson, Selby de Klerk, Craig McAndrew, Yann-Vaï Le Bihan, Mirco Meniconi, Rosemary Burke, Vladimir Kirkin, Rob L. M. van Montfort, Florence I. Raynaud, Olivia W. Rossanese, Benjamin R. Bellenie, and Swen Hoelder

Subjects
Gene Expression Regulation, Neoplastic, Mice, Carcinogenesis, Drug Discovery, Proto-Oncogene Proteins c-bcl-6, Animals, Humans, Molecular Medicine
Abstract

The transcriptional repressor BCL6 is an oncogenic driver found to be deregulated in lymphoid malignancies. Herein, we report the optimization of our previously reported benzimidazolone molecular glue-type degrader

Published
2022
Full Text
View/download PDF

3. Achieving

Author

Benjamin R, Bellenie, Kwai-Ming J, Cheung, Ana, Varela, Olivier A, Pierrat, Gavin W, Collie, Gary M, Box, Michael D, Bright, Sharon, Gowan, Angela, Hayes, Matthew J, Rodrigues, Kartika N, Shetty, Michael, Carter, Owen A, Davis, Alan T, Henley, Paolo, Innocenti, Louise D, Johnson, Manjuan, Liu, Selby, de Klerk, Yann-Vaï, Le Bihan, Matthew G, Lloyd, P Craig, McAndrew, Erald, Shehu, Rachel, Talbot, Hannah L, Woodward, Rosemary, Burke, Vladimir, Kirkin, Rob L M, van Montfort, Florence I, Raynaud, Olivia W, Rossanese, and Swen, Hoelder

Subjects
Male, Mice, Inbred BALB C, Mice, SCID, Xenograft Model Antitumor Assays, Article, Protein Structure, Tertiary, Rats, Rats, Sprague-Dawley, Mice, Drug Delivery Systems, immune system diseases, hemic and lymphatic diseases, Cell Line, Tumor, Drug Discovery, Microsomes, Liver, Proto-Oncogene Proteins c-bcl-6, Animals, Humans, Benzimidazoles, Female
Abstract

Deregulation of the transcriptional repressor BCL6 enables tumorigenesis of germinal center B-cells, and hence BCL6 has been proposed as a therapeutic target for the treatment of diffuse large B-cell lymphoma (DLBCL). Herein we report the discovery of a series of benzimidazolone inhibitors of the protein–protein interaction between BCL6 and its co-repressors. A subset of these inhibitors were found to cause rapid degradation of BCL6, and optimization of pharmacokinetic properties led to the discovery of 5-((5-chloro-2-((3R,5S)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (CCT369260), which reduces BCL6 levels in a lymphoma xenograft mouse model following oral dosing.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results